Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 2
2017 47
2018 119
2019 166
2020 133
2021 46
Text availability
Article attribute
Article type
Publication date

Search Results

425 results
Results by year
Filters applied: . Clear all
Page 1
Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology.
Seferovic PM, Ponikowski P, Anker SD, Bauersachs J, Chioncel O, Cleland JGF, de Boer RA, Drexel H, Ben Gal T, Hill L, Jaarsma T, Jankowska EA, Anker MS, Lainscak M, Lewis BS, McDonagh T, Metra M, Milicic D, Mullens W, Piepoli MF, Rosano G, Ruschitzka F, Volterrani M, Voors AA, Filippatos G, Coats AJS. Seferovic PM, et al. Eur J Heart Fail. 2019 Oct;21(10):1169-1186. doi: 10.1002/ejhf.1531. Epub 2019 Aug 30. Eur J Heart Fail. 2019. PMID: 31129923 Free article.
Specific new recommendations have been made based on the evidence from major trials published since 2016, including sodium-glucose co-transporter 2 inhibitors in type 2 diabetes mellitus, MitraClip for functional mitral regurgitation, atrial fibrillation ablation in HF, tafamidis …
Specific new recommendations have been made based on the evidence from major trials published since 2016, including sodium-glucose co-transp …
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.
Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, Lin KP, Vita G, Attarian S, Planté-Bordeneuve V, Mezei MM, Campistol JM, Buades J, Brannagan TH 3rd, Kim BJ, Oh J, Parman Y, Sekijima Y, Hawkins PN, Solomon SD, Polydefkis M, Dyck PJ, Gandhi PJ, Goyal S, Chen J, Strahs AL, Nochur SV, Sweetser MT, Garg PP, Vaishnaw AK, Gollob JA, Suhr OB. Adams D, et al. N Engl J Med. 2018 Jul 5;379(1):11-21. doi: 10.1056/NEJMoa1716153. N Engl J Med. 2018. PMID: 29972753 Free article. Clinical Trial.
BACKGROUND: Patisiran, an investigational RNA interference therapeutic agent, specifically inhibits hepatic synthesis of transthyretin. METHODS: In this phase 3 trial, we randomly assigned patients with hereditary transthyretin amyloidosis with polyneuropa
BACKGROUND: Patisiran, an investigational RNA interference therapeutic agent, specifically inhibits hepatic synthesis of transthyretin
How to Image Cardiac Amyloidosis: A Practical Approach.
Dorbala S, Cuddy S, Falk RH. Dorbala S, et al. JACC Cardiovasc Imaging. 2020 Jun;13(6):1368-1383. doi: 10.1016/j.jcmg.2019.07.015. Epub 2019 Oct 11. JACC Cardiovasc Imaging. 2020. PMID: 31607664 Free PMC article. Review.
Cardiac amyloidosis (CA) is one of the most rapidly progressive forms of heart disease, with a median survival from diagnosis, if untreated, ranging from <6 months for light chain amyloidosis to 3 to 5 years for transthyretin amyloidosis. ...
Cardiac amyloidosis (CA) is one of the most rapidly progressive forms of heart disease, with a median survival from diagnosis, if unt …
Neuropathy.
Pisciotta C, Shy ME. Pisciotta C, et al. Handb Clin Neurol. 2018;148:653-665. doi: 10.1016/B978-0-444-64076-5.00042-9. Handb Clin Neurol. 2018. PMID: 29478606 Review.
The genetic neuropathies are a clinically and genetically heterogeneous group of diseases that can broadly be classified into two groups: those in which the neuropathy is the sole or primary part of the disorder (Charcot-Marie-Tooth disease, CMT) and those in which the neuropathy …
The genetic neuropathies are a clinically and genetically heterogeneous group of diseases that can broadly be classified into two groups: th …
Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis.
Maurer MS, Bokhari S, Damy T, Dorbala S, Drachman BM, Fontana M, Grogan M, Kristen AV, Lousada I, Nativi-Nicolau J, Cristina Quarta C, Rapezzi C, Ruberg FL, Witteles R, Merlini G. Maurer MS, et al. Circ Heart Fail. 2019 Sep;12(9):e006075. doi: 10.1161/CIRCHEARTFAILURE.119.006075. Epub 2019 Sep 4. Circ Heart Fail. 2019. PMID: 31480867 Free PMC article. Review.
Cardiomyopathy is a manifestation of transthyretin amyloidosis (ATTR), which is an underrecognized systemic disease whereby the transthyretin protein misfolds to form fibrils that deposit in various tissues and organs. ...Considered a rare disease, ATTR am
Cardiomyopathy is a manifestation of transthyretin amyloidosis (ATTR), which is an underrecognized systemic disease whereby th …
Aortic Stenosis and Cardiac Amyloidosis: JACC Review Topic of the Week.
Ternacle J, Krapf L, Mohty D, Magne J, Nguyen A, Galat A, Gallet R, Teiger E, Côté N, Clavel MA, Tournoux F, Pibarot P, Damy T. Ternacle J, et al. J Am Coll Cardiol. 2019 Nov 26;74(21):2638-2651. doi: 10.1016/j.jacc.2019.09.056. J Am Coll Cardiol. 2019. PMID: 31753206 Free article. Review.
The prevalence of calcific aortic stenosis (AS) and of cardiac amyloidosis (CA) increases with age, and their association is not uncommon in the elderly. ...In case of suspicion of CA, it is thus crucial to confirm the diagnosis to guide therapeutic management of AS and ev …
The prevalence of calcific aortic stenosis (AS) and of cardiac amyloidosis (CA) increases with age, and their association is not unco …
Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment.
Siddiqi OK, Ruberg FL. Siddiqi OK, et al. Trends Cardiovasc Med. 2018 Jan;28(1):10-21. doi: 10.1016/j.tcm.2017.07.004. Epub 2017 Jul 13. Trends Cardiovasc Med. 2018. PMID: 28739313 Free PMC article. Review.
The natural history of the disease, involvement of other organs, and treatment options vary significantly based on the protein of origin. In AL amyloidosis, amyloid protein is derived from immunoglobulin light chains, and most often involves the kidneys and the hear …
The natural history of the disease, involvement of other organs, and treatment options vary significantly based on the protein of origin. In …
Neuropathy Associated with Systemic Amyloidosis.
Kaku M, Berk JL. Kaku M, et al. Semin Neurol. 2019 Oct;39(5):578-588. doi: 10.1055/s-0039-1688994. Epub 2019 Oct 22. Semin Neurol. 2019. PMID: 31639841 Review.
Peripheral neuropathy occurs in the setting of both hereditary and acquired amyloidosis. The most common form of hereditary amyloidosis is caused by 1 of 140 mutations in the transthyretin (TTR) gene, which can lead to neuropathic hereditary transthyretin
Peripheral neuropathy occurs in the setting of both hereditary and acquired amyloidosis. The most common form of hereditary amyloi
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.
Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Planté-Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheinberg M, Brannagan TH 3rd, Litchy WJ, Whelan C, Drachman BM, Adams D, Heitner SB, Conceição I, Schmidt HH, Vita G, Campistol JM, Gamez J, Gorevic PD, Gane E, Shah AM, Solomon SD, Monia BP, Hughes SG, Kwoh TJ, McEvoy BW, Jung SW, Baker BF, Ackermann EJ, Gertz MA, Coelho T. Benson MD, et al. N Engl J Med. 2018 Jul 5;379(1):22-31. doi: 10.1056/NEJMoa1716793. N Engl J Med. 2018. PMID: 29972757 Free article. Clinical Trial.
BACKGROUND: Hereditary transthyretin amyloidosis is caused by pathogenic single-nucleotide variants in the gene encoding transthyretin ( TTR) that induce transthyretin misfolding and systemic deposition of amyloid. Progressive amyloid acc …
BACKGROUND: Hereditary transthyretin amyloidosis is caused by pathogenic single-nucleotide variants in the gene encoding tr
Confirming the Diagnosis of Amyloidosis.
Wisniowski B, Wechalekar A. Wisniowski B, et al. Acta Haematol. 2020;143(4):312-321. doi: 10.1159/000508022. Epub 2020 Jun 16. Acta Haematol. 2020. PMID: 32544917 Free article. Review.
Cardiac transthyretin amyloidosis, however, may be diagnosed without a biopsy provided stringent criteria are met. ...Here we summarise the biopsy approach to amyloidosis, as well as the non-biopsy diagnosis of cardiac transthyretin amyloidosis. …
Cardiac transthyretin amyloidosis, however, may be diagnosed without a biopsy provided stringent criteria are met. ...Here we …
425 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page